INO 3510
Alternative Names: Fluprime; INO-3401/INO-3605/INO-3609; INO-3401/INO-3609/INO-3605; INO-3510; INO-3605/INO-3401/INO-3609; INO-3605/INO-3609/INO-3401; INO-3609/INO-3605/INO-3401; INO-3609/INO3401/INO-3605; Multi-subtype SynCon® vaccine targeting H1N1 and H5N1 influenza - Inovio; Seasonal flu vaccine (H5N1 + H1N1) - Inovio; SynCon H5N1 + H1N1 influenza universal vaccine - Inovio; Universal influenza (H5N1 + H1N1) SynCon vaccine - Inovio; VGX-3510Latest Information Update: 28 May 2018
At a glance
- Originator Inovio Pharmaceuticals
- Class Influenza A virus H1N1 vaccines; Influenza virus DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention, In volunteers) in USA (Intradermal, Injection)
- 28 May 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention, In volunteers) in USA (Intradermal, Injection)
- 02 May 2016 INO 3510 is still in phase I trials for Influenza-A virus H5N1 & H1N1 subtypes (Prevention, In volunteers) in USA